{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:57:22Z","timestamp":1777874242586,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T00:00:00Z","timestamp":1699142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\u201301702"],"award-info":[{"award-number":["PI18\u201301702"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.biopha.2023.115848","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T09:39:09Z","timestamp":1699954749000},"page":"115848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Combined analytical assays for the characterization of drugs binding to human IgE: Applicability to omalizumab-bearing biosimilar candidates assessment"],"prefix":"10.1016","volume":"169","author":[{"given":"Adri\u00e1n","family":"Urbano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Plaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7400-4993","authenticated-orcid":false,"given":"C\u00e9sar","family":"Picado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3002-6004","authenticated-orcid":false,"given":"Fernando","family":"de Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.115848_bib1","doi-asserted-by":"crossref","unstructured":"Magnenat L., Palmese A., Fremaux C., Amici F.D., Terlizzese M., Rossi M., et al. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira \u00ae, 2017; 0862. Available from: https:\/\/doi.org\/10.1080\/19420862.2016.1259046.","DOI":"10.1080\/19420862.2016.1259046"},{"issue":"1","key":"10.1016\/j.biopha.2023.115848_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s13238-017-0447-x","article-title":"Molecular and functional analysis of monoclonal antibodies in support of biologics development","volume":"9","author":"Wang","year":"2018","journal-title":"Protein Cell [Internet]"},{"issue":"4","key":"10.1016\/j.biopha.2023.115848_bib3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/19420862.2018.1438797","article-title":"Analytical comparability study of recombinant monoclonal antibody therapeutics","volume":"10","author":"Ambrogelly","year":"2018","journal-title":"MAbs [Internet]"},{"issue":"10","key":"10.1016\/j.biopha.2023.115848_bib4","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/14712598.2016.1217329","article-title":"Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel\u00ae)","volume":"16","author":"Hofmann","year":"2016","journal-title":"Expert Opin. Biol. Ther. [Internet]"},{"issue":"5","key":"10.1016\/j.biopha.2023.115848_bib5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1185\/03007995.2016.1145579","article-title":"Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents","volume":"32","author":"Vez\u00e9r","year":"2016","journal-title":"Curr. Med Res Opin. [Internet]"},{"issue":"4","key":"10.1016\/j.biopha.2023.115848_bib6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.xphs.2021.11.024","article-title":"Oxidation and deamidation of monoclonal antibody products: potential impact on stability, biological activity, and efficacy","volume":"111","author":"Gupta","year":"2022","journal-title":"J. Pharm. Sci. [Internet]"},{"issue":"4","key":"10.1016\/j.biopha.2023.115848_bib7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/14712598.2018.1421169","article-title":"Maintaining consistent quality and clinical performance of biopharmaceuticals","volume":"18","author":"Lamanna","year":"2018","journal-title":"Expert Opin. Biol. Ther. [Internet]"},{"key":"10.1016\/j.biopha.2023.115848_bib8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/9781118971147.ch15","article-title":"ICH Q5E comparability of biotechnological\/biological products subject to changes in their manufacturing processes","author":"Raghavan","year":"2017","journal-title":"ICH Qual. Guide"},{"key":"10.1016\/j.biopha.2023.115848_bib9","unstructured":"Agency E.M. June 2005 CPMP \/ ICH \/ 5721 \/ 03 ICH Topic Q 5 E Comparability of Biotechnological \/ Biological Products Step 5 NOTE FOR GUIDANCE ON BIOTECHNOLOGICAL \/ BIOLOGICAL PRODUCTS SUBJECT TO CHANGES IN THEIR MANUFACTURING PROCESS ( CPMP \/ ICH \/ 5721 \/ 03) TRANSM. 2005;(May 2004). Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-5-e-comparability-biotechnological\/biological-products-step-5_en.pdf\u3009."},{"issue":"2","key":"10.1016\/j.biopha.2023.115848_bib10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11095-015-1790-3","article-title":"Biosimilarity versus manufacturing change: two distinct concepts","volume":"33","author":"Declerck","year":"2016","journal-title":"Pharm. Res"},{"issue":"4","key":"10.1016\/j.biopha.2023.115848_bib11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40259-019-00360-7","article-title":"Biosimilars: a value proposition","volume":"33","author":"de Mora","year":"2019","journal-title":"BioDrugs [Internet]"},{"issue":"February","key":"10.1016\/j.biopha.2023.115848_bib12","first-page":"1","article-title":"Analytical similarity assessment of biosimilars: global regulatory landscape","volume":"10","author":"Nupur","year":"2022","journal-title":"Recent Stud. Major Adv. Orthogonal Platf."},{"issue":"5","key":"10.1016\/j.biopha.2023.115848_bib13","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.4161\/mabs.32221","article-title":"Physicochemical characterization of Remsima\u00ae","volume":"6","author":"Jung","year":"2014","journal-title":"MAbs [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2023.115848_bib14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.rbmo.2017.03.020","article-title":"Biosimilars to recombinant human FSH medicines: comparable efficacy and safety to the original biologic","volume":"35","author":"de Mora","year":"2017","journal-title":"Reprod. Biomed. Online [Internet]"},{"key":"10.1016\/j.biopha.2023.115848_bib15","unstructured":"Food and Drug Administration. NDA\/BLA Multi-disciplinary Review and Evaluation {BLA 103976, Supplement 5231}{Xolair\/Xolair} Reference ID: 4326577. September 8, 2017 for initial rollout (NME\/original BLA reviews) [Internet]. 2018 [cited 2020 Feb 9]. Available from: \u3008https:\/\/www.fda.gov\/media\/124199\/download\u3009."},{"key":"10.1016\/j.biopha.2023.115848_bib16","unstructured":"Fazel R., Guan Y., Vaziri B., Krisp C., Heikaus L., Saadati A., et al. Structural and In Vitro Functional Comparability Analysis of Altebrel \u2122, a Proposed Etanercept Biosimilar: Focus on Primary Sequence and Glycosylation.:1\u201316."},{"key":"10.1016\/j.biopha.2023.115848_bib17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.trac.2012.09.012","article-title":"Analytical strategies for the characterization of therapeutic monoclonal antibodies","volume":"42","author":"Fekete","year":"2013","journal-title":"Trends Anal. Chem. [Internet]"},{"key":"10.1016\/j.biopha.2023.115848_bib18","doi-asserted-by":"crossref","unstructured":"Pelaia C., Calabrese C., Terracciano R., Blasio F.De, Vatrella A., Pelaia G. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness, 2018; 1\u201316.","DOI":"10.1177\/1753466618810192"},{"issue":"May","key":"10.1016\/j.biopha.2023.115848_bib19","first-page":"1","article-title":"omalizumab-mediated IgE exchange","volume":"7","author":"Pennington","year":"2016","journal-title":"Nat. Commun. [Internet]"},{"key":"10.1016\/j.biopha.2023.115848_bib20","unstructured":"European Medicines Agency (EMA). Guideline on Comparability of Biotechnology-derived medicinal products after a change in the Manufacturing Process - Non-Clinical and Clinical Issues [Internet], 2007. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-comparability-biotechnology-derived-medicinal-products-after-change-manufacturing-process_en.pdf\u3009."},{"key":"10.1016\/j.biopha.2023.115848_bib22","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA\/CHMP\/BMWP\/42832\/2005) [Internet]. 2006. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-1.pdf\u3009."},{"issue":"1","key":"10.1016\/j.biopha.2023.115848_bib23","first-page":"1","article-title":"Evolution from adherent to suspension: systems biology of HEK293 cell line development","volume":"10","author":"Malm","year":"2020","journal-title":"Sci. Rep. [Internet]"},{"issue":"22","key":"10.1016\/j.biopha.2023.115848_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms20225520","article-title":"Description and characterization of a novel human mast cell line for scienti\ufb01c study","volume":"20","author":"Kirshenbaum","year":"2019","journal-title":"Int J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2023.115848_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003124","article-title":"Use of Humanised Rat Basophilic Leukaemia Cell Line RS-ATL8 for the Assessment of Allergenicity of Schistosoma mansoni Proteins","volume":"8","author":"Wan","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"13","key":"10.1016\/j.biopha.2023.115848_bib26","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.1074\/jbc.271.13.7494","article-title":"Identification of the high affinity receptor binding region in human immunoglobulin E","volume":"271","author":"Helm","year":"1996","journal-title":"J. Biol. Chem. [Internet]"},{"key":"10.1016\/j.biopha.2023.115848_bib27","doi-asserted-by":"crossref","unstructured":"Kuehn H.S., Radinger M., Gilfillan A.M. Measuring Mast Cell Mediator Release, 2010;1\u20139.","DOI":"10.1002\/0471142735.im0738s91"},{"issue":"4","key":"10.1016\/j.biopha.2023.115848_bib28","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.4049\/jimmunol.157.4.1645","article-title":"Anaphylaxis mediated through a humanized high affinity IgE receptor","volume":"157","author":"Dombrowicz","year":"1996","journal-title":"J. Immunol. [Internet]"},{"key":"10.1016\/j.biopha.2023.115848_bib29","article-title":"Nucleic acid encoding anti-ige antibodies [Internet].","volume":"Vol. 2","author":"Jardieu","year":"2008","journal-title":"U. S. ; US 7,351,816 B2"},{"issue":"3","key":"10.1016\/j.biopha.2023.115848_bib30","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.drudis.2018.01.009","article-title":"On the glycosylation aspects of biosimilarity","volume":"23","author":"Hajba","year":"2018","journal-title":"Drug Discov. Today [Internet]"},{"key":"10.1016\/j.biopha.2023.115848_bib31","series-title":"Advances in Protein Chemistry and Structural Biology","first-page":"97","article-title":"Catalytic activity regulation through post-translational modification: the expanding universe of protein diversity [Internet]. Vol. 122","author":"Kokkinidis","year":"2020"},{"issue":"2","key":"10.1016\/j.biopha.2023.115848_bib32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/cr.2013.151","article-title":"Protein post-translational modifications and regulation of pluripotency in human stem cells","volume":"24","author":"Wang","year":"2014","journal-title":"Cell Res [Internet]"},{"key":"10.1016\/j.biopha.2023.115848_bib33","article-title":"N-glycosylation structure \u2013 function characterization of omalizumab, an anti-asthma biotherapeutic product","volume":"209","author":"Szabo","year":"2022","journal-title":"J. Pharm. Biomed. Anal. [Internet]"},{"issue":"3","key":"10.1016\/j.biopha.2023.115848_bib34","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jbiotec.2012.06.038","article-title":"Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells","volume":"161","author":"Croset","year":"2012","journal-title":"J. Biotechnol. [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2023.115848_bib35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/19420862.2018.1532766","article-title":"The first World Health Organization International Standard for infliximab products: A step towards maintaining harmonized biological activity","volume":"11","author":"Metcalfe","year":"2019","journal-title":"MAbs [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2023.115848_bib36","first-page":"1","article-title":"A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma","volume":"17","author":"Harris","year":"2016","journal-title":"Respir. Res [Internet]"},{"issue":"11","key":"10.1016\/j.biopha.2023.115848_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12204","article-title":"Pharmacokinetic equivalence of CT-P39 and reference omalizumab in healthy individuals: A randomised, double-blind, parallel-group, Phase 1 trial","volume":"12","author":"Maurer","year":"2022","journal-title":"Clin. Transl. Allergy"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223016463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223016463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:23:36Z","timestamp":1777577016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223016463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":36,"alternative-id":["S0753332223016463"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115848","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined analytical assays for the characterization of drugs binding to human IgE: Applicability to omalizumab-bearing biosimilar candidates assessment","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115848","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115848"}}